BDX— AI Stock Forecast & Price Targets
Published 8/4/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live BDX price forecast →
BDX shows strong fundamentals with robust cash flow and key contracts, but near-term margin compression from recalls creates volatility. Technicals indicate upside potential within forecast bands amid improving momentum, though short interest and operational risks require caution.
Hold until earnings (Aug 6) — if price breaks above $175, consider a small long position; invalidation below $165
Accumulate on dips to $160-$165 with target of $180 by Q4 2026; catalysts include Vizient contract ramp-up and margin recovery
Long-term thesis hinges on successful execution of IV equipment market growth (6.1% CAGR) and regulatory approval for new products; structural risk is product recall frequency impacting margins
Revenue growth is mixed with Q1 2026 showing a -203.53% EPS decline, but strong cash flow ($4.53B FCF) and gross margins (47%) support quality. Balance sheet shows manageable debt-to-equity (0.72), though net margins are negative (-6.59%). Key contracts like Vizient provide growth catalysts, while the 19% undervaluation based on DCF suggests upside potential. However, operational risks from product recalls and margin compression create near-term headwinds.
Price has broken above $160 support with a strong upward trend since May, currently trading at $170.21. The Kronos AI forecast shows a tight band between 154.46 (low) and 169.60 (high), with actual price hovering near the upper end of the range. RSI (68.21) indicates bullish momentum, but short interest (3.78%) and recent volatility suggest caution. The SMA20 (7.97%) and SMA50 (11.90%) both show positive trends, supporting a continuation pattern.
Recent news highlights BDX's Brazil semaglutide partnership with EMS as a key catalyst for growth in chronic disease care. However, the 19% undervaluation based on DCF is offset by negative net margins and product recall risks. The $176.30 target price from analysts aligns with the forecast band but requires confirmation of margin recovery post-earnings.
- Vizient contract for CentroVena One expected to drive revenue growth in Q4 2026
- Brazil semaglutide launch with EMS to expand chronic disease care market share
- Product recalls causing near-term margin compression and operational delays
- Regulatory shifts impacting medical device approvals and pricing
- Negative net margins in the immediate term despite strong cash flow
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord